Mondobiotech is a company dedicated to discovering therapies to treat rare and neglected diseases. Our researchers analyze peptides of human origin to identify promising candidate drugs for development of treatments for rare diseases; partner companies then synthetically manufacture the candidate drugs. The analysis begins on the Internet, allowing Mondobiotech researchers to draw conclusions from the overwhelming amount of free information available in the life sciences literature regarding the potentially efficacious features of peptides for use as drugs to treat rare diseases. It is for this reason that Mondobiotech follows an Internet-Search-System rather than a classical Laboratory-Research-Concept as a basic framework for discovery. This innovative research model and business structure allow Mondobiotech to indentify a greater pool of medicinal candidates and to jumpstart drug development for many different rare diseases.
It must be noted that many naturally occurring human peptides consistently have several inherent biological functions; thus they can be used to treat a greater pool of conditions than those for which their effects were initially described. In addition, most of these are well researched and characterized molecules with obvious efficacies and, typically, low toxicity. To further develop the medicinal candidates beyond the search and match phase we interact with research scientists, experts in the field of drug formulation and administration, clinical researchers, and patients and their families. It is therefore integral to our philosophy to engage in intense Community Networking. The projects we generate are discussed in workshops attended by experts in the field to construct and fine-tune the clinical and development strategy. After a certain point, varying with each project, the patented and orphan drug designated medication is licensed to a well-qualified partner company for development so the drug can be delivered to the market.